Review
Clinical Neurology
Nirosen Vijiaratnam, Thomas Foltynie
Summary: The recent validation of the alpha-synuclein seed amplification assay as a biomarker for the diagnosis of Parkinson's disease has provided a basis for a proposed staging system in clinical studies. However, further challenges exist in finding biomarkers for disease modifying agents, including optimizing distinction between different alpha-synucleinopathies and predicting clinical benefit. The use of additional biomarkers, such as CSF proteins and imaging techniques, may enhance trial planning and assessment of interventions.
Review
Neurosciences
Simon R. W. Stott, Richard K. Wyse, Patrik Brundin
Summary: The international Linked Clinical Trials program is focused on providing disease-modifying drugs for Parkinson's disease, with seven completed and 15 ongoing clinical trials. This program, which has rapidly grown since its initial planning in 2010, aims to deliver disease modification in PD by evaluating 16 agents in clinical trials. The review provides an overview of the history, structure, process, progress, and examples of agents selected and evaluated by the program.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Geriatrics & Gerontology
Zoltan Mari, Tiago A. Mestre
Summary: Parkinson's disease (PD) remains a progressive disease without a cure, despite the successful development of symptomatic treatments. The translation of disease-modifying interventions from preclinical models to clinical success has faced challenges in the past two decades. Lessons learned from high-quality clinical trials and advancements in PD molecular pathology can provide deeper insights into past failures and guide future research.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Review
Neurosciences
Mohammad Yasin Zamanian, Mehraveh Sadeghi Ivraghi, Reena Gupta, K. D. V. Prasad, Hashem O. Alsaab, Beneen M. Hussien, Hazem Ahmed, Montather F. Ramadan, Maryam Golmohammadi, Nikta Nikbakht, Tuba Oz, Malgorzata Kujawska
Summary: Parkinson's disease is a neurodegenerative disorder involving various cellular and molecular mechanisms. miR-221 plays important roles in protecting neuronal cells and regulating cell survival and apoptosis in PD. It also has the potential to be used as a clinical biomarker for PD diagnosis and stage assignment.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2023)
Article
Neurosciences
Cristina Gonzalez-Robles, Rimona S. Weil, Daniel van Wamelen, Michele Bartlett, Matthew Burnell, Caroline S. Clarke, Michele T. Hu, Brook Huxford, Ashwani Jha, Christian Lambert, Michael Lawton, Georgia Mills, Alastair Noyce, Paola Piccini, Kuhan Pushparatnam, Lynn Rochester, Carroll Siu, Caroline H. Williams-Gray, Marie-Louise Zeissler, Henrik Zetterberg, Camille B. Carroll, Thomas Foltynie, Anette Schrag
Summary: This study aims to provide an inventory of outcome measures (OM) for disease-modifying trials in Parkinson's disease and a framework for future selection of OM. An extensive inventory of OM was created based on evidence evaluation. Patient and public involvement emphasized the need for OM reflecting their disease experience and applicable to diverse populations and disease stages.
JOURNAL OF PARKINSONS DISEASE
(2023)
Article
Food Science & Technology
Yujie Chen, Wuke Yuan, Qi Xu, Manju B. Reddy
Summary: Parkinson's disease (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders with shared molecular mechanisms, and there is currently no effective treatment. However, research suggests that consuming phytochemicals may help delay the progression of these diseases.
JOURNAL OF FUNCTIONAL FOODS
(2023)
Review
Neurosciences
Philipp Mahlknecht, Kathrin Marini, Mario Werkmann, Werner Poewe, Klaus Seppi
Summary: The ultimate goal of PD research is to find treatments that can slow down or stop the progression of the disease. Past disease-modification trials in PD have failed due to various factors, including wrong intervention choices, inadequate trial designs, and target populations. Prospective studies have provided sufficient evidence for defining diagnostic criteria for prodromal PD, and different approaches have been studied in observational cohorts. This review discusses recruitment strategies, trial designs, trial durations, and sample sizes for disease-modification trials in prodromal PD cohorts, and offers an outlook on how this goal can be achieved in the future.
TRANSLATIONAL NEURODEGENERATION
(2022)
Review
Pharmacology & Pharmacy
Xin-xing Yang, Rong Yang, Feng Zhang
Summary: Parkinson's disease is a common and chronic degenerative disease in the central nervous system. The main pathology involves the loss of dopaminergic neurons and the formation of Lewy bodies. The pathogenesis of PD is influenced by various independent factors, and regulating the Nrf2 pathway may be a promising strategy for preventing and treating PD.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Neurosciences
Ilham Y. Abdi, Simona S. Ghanem, Omar M. El-Agnaf
Summary: Despite being the second most common neurodegenerative disorder in the world, Parkinson's disease lacks established diagnostic markers or disease modifying therapies. Recent evidence suggests that the immune system may play a role in the pathogenesis of the disease, although the exact nature of this involvement is still debated.
NEUROBIOLOGY OF DISEASE
(2022)
Article
Multidisciplinary Sciences
J. Brucker Nourse, Shannon N. Russell, Nathan A. Moniz, Kylie Peter, Lena M. Seyfarth, Madison Scott, Han-A Park, Kim A. Caldwell, Guy A. Caldwell
Summary: This study investigates the TNK2 gene variants in Parkinson's disease (PD) patients and their potential impact on dopaminergic neurodegeneration. The findings suggest that TNK2 dysfunction may contribute to PD, possibly through sustained or aberrant activity. The study also highlights the importance of TNK2 and its ortholog SID-3 in coordinating dopaminergic and epigenetic signaling. Experimental results using Caenorhabditis elegans and rat primary neurons demonstrate the neuroprotective effects of TNK2 inhibition and NEDD4 activation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Biochemical Research Methods
Adriana Zardini Buzatto, Jaspaul Tatlay, Barinder Bajwa, Dorothea Mung, Richard Camicioli, Roger A. Dixon, Liang Li
Summary: This study focused on discovering biomarkers for Parkinson's disease (PD) and predicting the transition to dementia using untargeted lipidomics. The proposed biomarker panels showed excellent performance in differentiating PD patients from healthy controls and identifying PD patients at risk of developing dementia. Further research with a larger sample size is needed to validate these findings.
JOURNAL OF PROTEOME RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Olga Wojciechowska, Malgorzata Kujawska
Summary: Parkinson's disease (PD) is a chronic neurodegenerative disorder with complex pathophysiology and symptoms. Polyphenols, especially urolithin A (UA), have shown beneficial effects on neurodegeneration. UA, produced by dietary ellagitannins and ellagic acid, has anti-inflammatory, antioxidant, and anti-apoptotic properties. This review organizes the existing knowledge on the role of UA in neuroprotection, particularly in PD, and explores potential future applications in PD management.
Review
Biochemistry & Molecular Biology
Suman Chowdhury, Robert Ledeen
Summary: In this review, we summarize our findings of a systemic deficiency of ganglioside GM1 in Parkinson's disease (PD) tissues. The deficiency is observed in various neuronal and non-neuronal tissues, which suggests a potential underlying mechanism for loss of neuronal viability and normal functioning. We discuss the causes of these deficiencies and propose GM1 replacement as a potential therapy for PD based on strong evidence from animal studies and clinical trials.
Review
Clinical Neurology
David Devos, Etienne Hirsch, Richard Wyse
Summary: In the development of neuroprotective drugs for Parkinson's disease (PD), it is important to target specific patients, combine multiple treatments, establish early interventions and improve biomarkers, customize drugs, prioritize repurposed drugs, and adapt preclinical models with translational biomarkers.
MOVEMENT DISORDERS
(2021)
Article
Neurosciences
Heba Fikry, Lobna A. Saleh, Sara Abdel Gawad
Summary: This study investigated the protective influence of curcumin on the cerebellum of rats with rotenone-induced Parkinson's disease. The results showed that curcumin could alleviate degenerative changes and neurotoxic effects in the cerebellum, as well as reduce oxidative stress. This suggests that dietary supplementation of curcumin may have neuroprotective effects against cerebellum-related Parkinson's disease symptoms.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)
Editorial Material
Clinical Neurology
A. Jon Stoessl, Kailash P. Bhatia, Marcelo Merello
MOVEMENT DISORDERS
(2020)
Article
Clinical Neurology
Zahinoor Ismail, Sandra E. Black, Richard Camicioli, Howard Chertkow, Nathan Herrmann, Robert Laforce, Manuel Montero-Odasso, Kenneth Rockwood, Pedro Rosa-Neto, Dallas Seitz, Saskia Sivananthan, Eric E. Smith, Jean-Paul Soucy, Isabelle Vedel, Serge Gauthier
ALZHEIMERS & DEMENTIA
(2020)
Editorial Material
Clinical Neurology
A. Jon Stoessl
Review
Neurosciences
Roger A. Barker, Anders Bjorklund, Don M. Gash, Alan Whone, Amber Van Laar, Jeffrey H. Kordower, Krystof Bankiewicz, Karl Kieburtz, Mart Saarma, Sigrid Booms, Henri J. Huttunen, Adrian P. Kells, Massimo S. Fiandaca, A. Jon Stoessl, David Eidelberg, Howard Federoff, Merja H. Voutilainen, David T. Dexter, Jamie Eberling, Patrik Brundin, Lyndsey Isaacs, Leah Mursaleen, Eros Bresolin, Camille Carroll, Alasdair Coles, Brian Fiske, Helen Matthews, Codrin Lungu, Richard K. Wyse, Simon Stott, Anthony E. Lang
JOURNAL OF PARKINSONS DISEASE
(2020)
Letter
Clinical Neurology
Alexandra Pavel, Danielle K. Murray, A. Jon Stoessl
Editorial Material
Clinical Neurology
A. Jon Stoessl
MOVEMENT DISORDERS
(2021)
Article
Neurosciences
Megan P. Feeney, Danny Bega, Benzi M. Kluger, A. Jon Stoessl, Christiana M. Evers, Rebeca De Leon, James C. Beck
Summary: A survey found that approximately a quarter of people with Parkinson's disease in the United States had used cannabis in the past six months, primarily to alleviate non-motor symptoms such as anxiety, pain, and sleep disorders. Lack of scientific evidence supporting the efficacy of cannabis for PD has led to cautious attitudes towards its use among patients.
NPJ PARKINSONS DISEASE
(2021)
Review
Clinical Neurology
Valtteri Kaasinen, Tero Vahlberg, A. Jon Stoessl, Antonio P. Strafella, Angelo Antonini
Summary: This study conducted a systematic review and meta-analysis on the expression of dopamine receptors in PD, PSP, and MSA, revealing differences in binding values of dopamine receptors among patients with different diseases.
MOVEMENT DISORDERS
(2021)
Review
Clinical Neurology
Trina Mitchell, Stephane Lehericy, Shannon Y. Chiu, Antonio P. Strafella, A. Jon Stoessl, David E. Vaillancourt
Summary: Imaging biomarkers for different stages of Parkinson's disease are crucial for monitoring progression in clinical trials and improving clinical care. This review highlights the importance of considering disease stage when implementing diagnostic and progression biomarkers in both clinical trials and clinical care settings.
Editorial Material
Clinical Neurology
A. Jon Stoessl
MOVEMENT DISORDERS
(2022)
Article
Multidisciplinary Sciences
Mariya V. Cherkasova, Jessie F. Fu, Michael Jarrett, Poljanka Johnson, Shawna Abel, Roger Tam, Alexander Rauscher, Vesna Sossi, Shannon Kolind, David K. B. Li, A. Dessa Sadovnick, Lindsay Machan, J. Marc Girard, Francois Emond, Reza Vosoughi, Anthony Traboulsee, A. Jon Stoessl
Summary: Despite limited therapeutic effects, certain multiple sclerosis patients demonstrated a transient improvement in health-related quality of life, indicating a placebo response. The study found that placebo responders had higher lesion activity and exhibited a different cortical architecture compared to non-responders.
SCIENTIFIC REPORTS
(2022)
Editorial Material
Clinical Neurology
A. Jon Stoessl
MOVEMENT DISORDERS
(2022)
Article
Clinical Neurology
Jessie F. Fu, Michele Matarazzo, Jessamyn McKenzie, Nicole Neilson, Nasim Vafai, Katie Dinelle, Andre C. Felicio, Martin J. McKeown, A. Jon Stoessl, Vesna Sossi
Summary: The study found that the serotonergic system contributes to dopamine release and increases the risk for motor complications in early Parkinson's disease. Moreover, this contribution fails to provide sustained therapeutic advantage in early disease.
MOVEMENT DISORDERS
(2021)
Article
Neuroimaging
Jessie Fanglu Fu, Ivan S. Klyuzhin, Martin J. McKeown, A. Jon Stoessl, Vesna Sossi
NEUROIMAGE-CLINICAL
(2020)
Review
Clinical Neurology
Melanie Brisson, Catherine Brodeur, Laurent Letourneau-Guillon, Mario Masellis, Jon Stoessl, Alex Tamm, Katherine Zukotynski, Zahinoor Ismail, Serge Gauthier, Pedro Rosa-Neto, Jean-Paul Soucy
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
(2020)
